Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing EL… Read more
Elicera Therapeutics AB (ELIC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.156x
Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has a cash flow conversion efficiency ratio of -0.156x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.74 Million) by net assets (Skr30.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Elicera Therapeutics AB - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Elicera Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Elicera Therapeutics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elicera Therapeutics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DJ Mediaprint & Logistics Limited
NSE:DJML
|
0.037x |
|
Filatex Fashions Limited
NSE:FILATFASH
|
N/A |
|
Globe International Ltd
AU:GLB
|
0.030x |
|
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
|
-0.005x |
|
477380
KQ:477380
|
N/A |
|
RE Royalties Ltd
OTCQX:RROYF
|
0.166x |
|
Investeringsselskabet Luxor A/S
CO:LUXOR-B
|
0.030x |
|
Selangor Dredging Bhd
KLSE:2224
|
0.061x |
Annual Cash Flow Conversion Efficiency for Elicera Therapeutics AB (2017–2024)
The table below shows the annual cash flow conversion efficiency of Elicera Therapeutics AB from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr20.77 Million | Skr-23.46 Million | -1.130x | -24.16% |
| 2023-12-31 | Skr16.40 Million | Skr-14.92 Million | -0.910x | -248.18% |
| 2022-12-31 | Skr32.80 Million | Skr-8.57 Million | -0.261x | +4.50% |
| 2021-12-31 | Skr52.24 Million | Skr-14.29 Million | -0.274x | -209.39% |
| 2020-12-31 | Skr10.24 Million | Skr-905.25K | -0.088x | +77.29% |
| 2019-12-31 | Skr614.10K | Skr-239.16K | -0.389x | -31.11% |
| 2018-12-31 | Skr805.16K | Skr-239.16K | -0.297x | -0.44% |
| 2017-12-31 | Skr808.69K | Skr-239.16K | -0.296x | -- |